Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Rheumatology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Rheumatology

Journal Scan / Research · January 31, 2023

Long-Term Effectiveness and Persistence of Using Ustekinumab vs TNF Inhibitors in Patients With Psoriatic Arthritis

Annals of the Rheumatic Diseases


Additional Info

Annals of the Rheumatic Diseases
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Ann. Rheum. Dis 2022 Dec 13;[EPub Ahead of Print], L Gossec, S Siebert, P Bergmans, K de Vlam, E Gremese, B Joven-Ibáñez, TV Korotaeva, F Lavie, W Noël, MT Nurmohamed, PP Sfikakis, M Sharaf, E Theander, JS Smolen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading